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CASE REPORT
Low-grade central fibroblastic 
osteosarcoma may be differentiated from its 
mimicker desmoplastic fibroma by genetic 
analysis
Wangzhao Song1, Eva van den Berg2, Thomas C. Kwee3, Paul C. Jutte4, Anne‑Marie Cleton‑Jansen5, 
Judith V. M. G. Bovée5 and Albert J. Suurmeijer1* 
Abstract 
Background: We studied two cases of rare fibrous bone tumors, namely desmoplastic fibroma (DF) and low‑grade 
central osteosarcoma (LGCOS) resembling desmoplastic fibroma (DF‑like LGCOS). As the clinical presentation, imaging 
features and histopathology of DF and DF‑like LGOS show much overlap, the objective of this study was to investigate 
the value of cytogenetic analysis, molecular pathology and immunohistochemistry in discrimination of these two 
mimickers.
Case presentation: A mutation in CTNNB (S45F) and nuclear beta‑catenin immunostaining were observed in DF. DF‑
LGCOS had amplification of CDK4 and showed strong nuclear expression of CDK4 by IHC. Moreover, the karyotype of 
DF‑LGCOS showed an interstitial heterozygous deletion of the long arm of chromosome 13 (q12q32), associated with 
loss of the RB1 tumor suppressor gene.
Conclusions: Karyotyping and molecular genetic analysis may contribute to a conclusive diagnosis.
Keywords: Bone sarcoma, Desmoplastic fibroma, Low‑grade osteosarcoma, CDK4, RB1
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Background
The histopathological diagnosis of bone tumors is usu-
ally rather straightforward, since the most common bone 
tumors show differentiation along osteoblastic or chond-
roblastic lines, and form bone matrix or cartilage, which 
usually can be easily detected in routinely stained tissue 
sections.
In the past decades, advances in the field of immuno-
histochemistry (IHC) and molecular pathology have 
allowed a precise diagnosis in difficult cases. Examples 
are IHC for SATB2 to confirm a tentative diagnosis of 
osteosarcoma, molecular DNA analysis for nonrandom 
gene translocations to differentiate Ewing sarcoma from 
other round cell sarcomas, and detection of H3F3A muta-
tions to accurately diagnose giant cell tumor of bone.
However, for fibrous tumors of bone the incremental 
value of IHC and DNA methods over standard basic his-
tology is rather limited. This category of fibrous tumors 
of bone includes the desmoplastic fibroma (DF)—a rare, 
locally aggressive tumor—and fibrosarcoma—a tumor 
once considered to be very common, but currently a 
diagnosis of exclusion, that one is only allowed to make 
after having ruled out other spindle cell tumors, e.g. low 
grade myofibroblastic sarcoma, myoepithelial tumors, 
follicular dendritic cell tumors, synovial sarcoma, and, 
last but not least, a rare variant of low-grade central oste-
osarcoma (LGCOS) resembling desmoplastic fibroma 
(DF-like LGCOS).
By co-incidence, two patients with these rare bone 
tumors (DF and DF-LGCOS) were treated in our 
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sarcoma center in the same week. In addition to IHC, we 
decided to apply classic cytogenetics and next generation 
sequencing (NGS), which proved to be very helpful in 
discriminating these two morphologic mimickers.
Case presentation
Case 1: a 10-year-old girl, with a history of distal radius 
fracture 3 years earlier, presented with a firm, nontender 
swelling in the same right distal forearm. Her wrist func-
tion was unimpaired. As shown in Fig.  1, X-ray exami-
nation revealed a large lobulated, compartmentalized, 
osteolytic, expansive tumor mass in the metadiaphy-
sis of the distal radius. On MRI, the tumor measured 
35 × 46 × 47  mm and had a well-defined boundary, but 
no sclerotic margin. Starting from the distal radius, 
there was cortical destruction, an extensive soft tissue 
component, and impression and bowing of the distal 
ulna. There were no imaging signs of invasive growth, 
necrosis or fluid-liquid mirrors. Bone scintigraphy did 
not show increased uptake at the location of the lesion. 
These imaging features were consistent with a destructive 
tumor that originated from the distal radius, grew slowly, 
and then broke through the cortex of the radius into 
the adjacent soft tissue. The tumor was excised intral-
esionally. Grossly, the largest tumor fragment measured 
6 × 5 × 3  cm. On cut surface the tumor tissue was pale 
and fibrous.
Tumor histology was reminiscent of desmoid fibroma-
tosis and consistent with desmoplastic fibroma, as it 
showed a lesion composed of bundles of moderately cel-
lular, collagenous tumor tissue with fibroblastic spindle 
cells with oval, monomorphic nuclei with bland, finely 
granular chromatin, small nucleoli and ample cytoplasm. 
Mitoses were not found (Fig. 2a).
Cytogenetic analysis revealed a normal female kar-
yotype in 18 cells, with trisomy 8 detected in 2 cells 
(Fig. 2b).
The cancer hotspot NGS analysis revealed a CTNNB1 
hotspot class 5 pathogenic variant in exon 3: p.Ser45Phe 
and, using IHC, the fibroblastic tumor cells showed more 
than focal nuclear staining for beta-catenin (Fig.  2c), in 
support of a diagnosis of desmoplastic fibroma.
Case 2: a 24-year-old woman presented with pro-
gressive pain in the right hip region that had existed 
for 1  year. X-ray images showed an osteolytic tumor in 
the metadiaphysis of the right distal femur with corti-
cal bone destruction on the dorsolateral side. The cen-
tral part of the tumor had no matrix calcification. On 
MRI, the tumor destroyed the cortex and extended to 
the surrounding soft tissues. There was strong tumor 
enhancement after administration of intravenous gado-
linium (Fig.  3a). A resection of the right distal femur 
was performed. The tumor in the distal femur measured 
12 × 4 cm. On cut surface the tumor was pale and fibrous. 
There was extension to surrounding soft tissue (Fig. 3b).
Tumor histology strongly resembled the desmoplastic 
fibroma diagnosed in case 1, however, with some differ-
ences. As shown in Fig. 4a, this tumor also consisted of 
bundles of moderate cellular tissue, with fibroblast-like, 
spindle cells in abundant collagenous stroma. However, 
there was evidence of invasive growth in trabecular bone 
and surrounding skeletal muscle tissue. Although nuclear 
chromatin was bland, few normal mitoses were found. 
Osteoid or trabecular bone was absent.
As depicted in Fig.  4b, cytogenetic analysis showed 
an abnormal karyotype: 47~49,XX,del(13) (q12q32),+ 
1~2r,+1~2mar,1dmin [cp17]/46,XX [2]. This encom-
passes an interstitial deletion of the long arm of chro-
mosome 13 (q12q32), consistent with heterozygous 
loss of the RB1 tumor suppressor gene. With cancer 
hotspot NGS analysis we found amplification of CDK4 
(NM_000075.3) and an imbalance of the RB1 gene on 
chromosome 13.
With IHC, tumor cells exhibited strong nuclear stain-
ing for CDK4 (Fig. 4c) and moderate nuclear staining for 
SATB2. RB1 expression was heterogeneous, not com-
pletely lost.
In this case a conclusive diagnosis of DF-LGOS could 
be made, based on histologic features (an invasive fibro-
blastic tumor with mitotic activity), karyotyping (het-
erozygous loss of RB1) and molecular genetics/IHC 
(CDK4 amplification).
Discussion and conclusions
We have presented the clinical presentation, imaging 
studies, gross and microscopic pathology, IHC, cytoge-
netics and molecular genetics (cancer hotspot analysis) 
of DF and DF-LCOS, two very rare bone tumors, which 
closely resemble each other.
DF is very rare indeed. Among 4692 benign bone 
tumors treated in the Birmingham Royal Orthopedic 
Hospital, Evans et  al. [1] identified 13 cases of DF, an 
incidence of 0.003%. Böhm et al. [2] reviewed 189 cases 
of DF reported in the literature up to 1996 and observed 
that, although DF occurs at all ages, children and young 
adults are most commonly affected, three-quarter of 
patients being younger than 31 years. Sex distribution is 
almost equal. DF most commonly presents in the man-
dible (22%), but also in pelvic bones (13%), and long 
bones—femur (15%), radius (12%), and tibia (9%). Nota-
bly, pathologic fracture of a long bone was reported in 
12% of patients. Thus, the clinical presentation of our 
DF case as a tumor in the distal radius of a 10-year-old 
girl, who had experienced a radius fracture 3 years earlier, 
matches data from the literature.
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Fig. 1 Conventional AP and lateral radiographs (top left and top middle) show an expansive bubbly lytic bone lesion in the diaphysis‑metaphysis 
of the right distal radius with a narrow zone of transition, nonsclerotic margins, cortical thinning and destruction, and an accompanying large 
soft‑tissue mass which appears to compress the distal ulna with bowing of the latter. Bone scintigraphy (top right) shows no increased uptake at 
the location of the lesion. MRI with coronal T1‑weighted (bottom left) and gadolinium‑enhanced T1‑weighted (bottom middle) images, and axial 
T2‑weighted and gadolinium‑enhanced fat‑suppressed T1‑weighted images (bottom right) are in keeping with the conventional radiographic 
findings, and also demonstrate no signs of invasion in surrounding muscles or ulna. Remarkably, in the center of the lesion there is low signal on 
all sequences (arrows), most strikingly on the T2‑weighted sequence. Because the combined imaging features suggest a slow‑growing (most likely 
benign) process with fibrotic components, the differential diagnostic considerations include desmoplastic fibroma, and (less likely) giant‑cell tumor 
or fibrous dysplasia
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It is well appreciated that DF has a high recurrence rate 
after intralesional excision [1, 2], but since DF is a benign 
tumor that does not metastasize, we choose to remove 
the radius tumor of this young girl intralesionally, in 
order to preserve arm and wrist function. Unfortunately, 
a recurrence has occurred 12 months after surgery.
As our case illustrates, DF may present as a slowly pro-
gressive but locally aggressive tumor. As reviewed by 
Nedopil et  al. [3] by imaging studies, DF can show cor-
tical breakthrough and extension in surrounding soft 
tissue.
Moreover, infiltrative tumor growth may be seen by 
microscopy. Mitoses are only rarely found, an important 
criterion to discriminate DF from DF-LCOS or low-grade 
fibrosarcoma [4].
Cytogenetic analysis of our DF case revealed a normal 
female karyotype in 18 cells, with a trisomy 8 detected 
in 2 cells. To our knowledge, only two papers have been 
published on the cytogenetics and molecular genetics of 
DF. Bridge et al. [5] found trisomies 8 and 20 in a single 
case of DF, but again, these cytogenetic abnormalities 
were also detected in other fibro-osseous bone tumors, 
Fig. 2 Histology, karyotype and beta‑catenin nuclear expression in DF. a Histology showing a fibroblastic tumor with little or no nuclear atypia 
or mitotic activity (H&E, original magnification × 200). As such, the histology of DF resembles that DF‑LGCOS shown in Fig. 4a. b DF karyotype: 
47,XX,+8[2]/46,XX[18]. c IHC expression of beta‑catenin in several tumor cell nuclei of DF (original magnification × 400)
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by which these are noncontributory to a certain DF 
diagnosis.
An abnormal karyotype 46,XX,del(11)(q13q23),der(19)
t(11;19)(q13;p13)del(11)(q23) was reported by Trombetta 
et al. [6] in a DF occurring in the femur of a 20-year-old 
female patient. It was hypothesized that loss of a genomic 
region in 11q, an area containing the genes RBM14, 
RBM4, RBM4B, SPTBN2, and C11orf80 may be of patho-
genic significance.
Using IHC, others and we have noticed nuclear stain-
ing of beta-catenin in DF [3, 4, 7–11]. However, although 
nuclear expression of beta-catenin supports a diagnosis 
of DF, one has to be aware that nuclear immunostaining 
of beta-catenin also occurs in other fibro-osseous bone 
tumors [9] or fibrous soft tissue tumors [12]. Moreover, 
IHC for beta-catenin is not specific for APC/CTNNB1 
mutations in fibro-osseous bone tumors. CTNNB1 muta-
tions are a rare molecular event in the few cases of DF 
that have been analyzed [7–9]. In fact, Flucke et  al. [8] 
found a p.T41A CTNNB1 mutation in 1 out of 2 cases of 
DF arising in the mandible, Horvai and Jordan [9] found 
an APC mutation, but no CTNNB1 mutation in a single 
DF analyzed, and Hauben et  al. [7] found no CTNNB1 
mutation in six DF cases. Using NGS, we detected a 
CTNNB1 hotspot class 5 pathogenic variant in exon 3: 
p.S45F, which is a gain of function mutation. Clearly, to 
be able to estimate the real frequency of CTNNB1 muta-
tions in DF, more cases have to be studied, preferably 
Fig. 3 Conventional AP, lateral radiographs and gross morphology of DF‑LGCOS. a Conventional AP, lateral radiographs (top left and top middle) 
show an expansive osteolytic lesion in the diaphysis‑metaphysis of the right distal femur with an ill‑defined border and cortical destruction. 
Bone scintigraphy (top right) demonstrates increased uptake at the location of the lesion, but no suspicious uptake elsewhere. MRI with sagittal 
T1‑weighted (bottom left) and fat‑suppressed proton density‑weighted (bottom middle) images, and axial T1‑weighted and gadolinium‑enhanced 
fat‑suppressed T1‑weighted images (bottom right) show the T1 hypointense, T2 hyperintense, and vividly enhancing lesion in the right distal femur 
as a large soft‑tissue mass with cortical breakthrough and extra‑osseous expansion. The combined imaging features are highly suggestive of an 
aggressive malignant lesion, with osteosarcoma, Ewing sarcoma, and chondrosarcoma being the main differential diagnostic considerations. b 
Gross specimen of DF‑LGCOS, showing a white, fibrous tumor of the distal femur with cortical breakthrough and invasion of soft tissue. As such, the 
gross appearance of DF‑LGCOS resembles DF
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using NGS, since NGS has a higher sensitivity compared 
with traditional DNA sequencing methods in picking up 
CTNNB1 mutations [13] Interestingly, the S45F CTNNB 
mutation also occurs in desmoid fibromatosis, in particu-
lar in aggressive and recurrent lesions [14]. However, it 
remains to be proven that DF is the bony counterpart of 
desmoid fibromatosis of soft tissue. In this respect, one 
may argue whether our case 1 represents a soft tissue 
tumor that had invaded bone. However, given the imag-
ing features, in particular the bubbly compartmental-
ized appearance of the radius tumor and the bowing of 
the distal ulna without bone invasion (see Fig.  1), we 
regarded the radius tumor in this girl as a slow growing 
primary bone tumor with soft tissue extension, a clinical 
presentation consistent with a histopathologic diagnosis 
of desmoplastic fibroma of bone.
Fig. 4 Histology, karyotype and CDK4 expression in DF‑LGOS. a Histology showing a fibroblastic tumor with permeative invasive growth (H&E, 
original magnification × 100). As such, the histology of DF‑LGCOS resembles that of DF, shown in Fig. 2a. b DF‑LGOS karyotype: 47~49,XX,del(13)
(q12q32),+1~2r,+1~2mar,1dmin[cp17]/46,XX[2]. c Diffuse nuclear expression of CDK4 in cell nuclei of DF‑LGCOS (original magnification × 200)
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The majority of central osteosarcomas are high-
grade conventional osteosarcomas, in which the tumor 
cells show severe nuclear atypia and produce a variable 
amount of cartilaginous or osteoid matrix. High grade 
osteosarcomas with severe nuclear atypia, but little or no 
matrix formation can be confirmed by SATB2 immuno-
histochemistry [15, 16].
Our DF-LGCOS case is part of another subset of low 
grade central osteosarcomas namely the ones that resem-
ble DF and have little or no osteoid matrix deposition. So 
far, this very rare OS subtype has only been described in 
case reports and small series [17, 18]. Most likely these 
rare DF-LCOS have been included in the histological 
spectrum of fibrosarcomas of bone [4]. We agree with 
Horvai and Jordan [9], who stated that it seems logical 
that at least a subset of fibrosarcomas of bone are actu-
ally osteosarcomas with little or no osteoid or bone for-
mation. Surprisingly, in the 2013 WHO classification of 
tumors of soft tissue and bone, fibrosarcomas of bone are 
defined as intermediate to high grade spindle cell tumors 
that lack any line of differentiation other than fibroblas-
tic, leaving little room for the recognition of low grade 
variants, also excluding DF- LGCOS.
Strong and diffuse SATB2 nuclear IHC staining reflects 
an osteoblastic line of differentiation. To date, only one 
Chinese study investigated SATB2 expression in low 
grade osteosarcoma and desmoplastic fibroma. These 
authors found that low-grade osteosarcoma and fibrous 
dysplasia are positive for SATB2, while desmoplas-
tic fibroma, low-grade fibrosarcoma and other fibrous 
tumors are negative [19].
The notion that DF-LGCOS is an osteosarcoma vari-
ant is also supported by the cytogenetics and molecular 
genetics of our second case. DF-LGCOS had a karyotype 
with interstitial deletion of the long arm of chromosome 
13 (q12q32), consistent with loss of the RB1 tumor sup-
pressor gene, a genetic abnormality found in a substantial 
number of osteosarcomas. Notably, cancer hotspot NGS 
analysis revealed amplification of CDK4 and IHC showed 
overexpression of CDK4.
The prototypical LGCOS (which resembles parosteal 
osteosarcoma) usually produces abundant bone matrix 
and contains trabecular woven bone. The fibroblas-
tic stromal cells of the prototypical LGCOS show slight 
nuclear atypia and mitosis are not easily discerned. This 
subset of LGCOS often has gain or amplification of the 
MDM2 and/or CDK4 genes, which can be visualized by 
their nuclear expression by IHC [19]. By IHC, CDK4 is 
positive in the majority of LGOS, and, when combined 
with MDM2 immunostaining, the sensitivity and speci-
ficity for LGOS is 100% and 97.5%, respectively [20].
The clinical presentation, imaging studies and gross 
morphology of DF-LGCOS shows much overlap with 
DF. Both are fibrous tumors of bone with are slowly 
progressive and locally aggressive showing cortical 
breakthrough. DF and DF-LGCOS consist of bundles of 
moderately cellular collagenous tumor tissue with spin-
dled fibroblast-like cells. The two cases reported herein 
show that karyotyping and molecular genetic analysis 
may contribute to a conclusive diagnosis, DF show-
ing CTNNB1 S45F mutation and DF-LGCOS showing 
CDK4 amplification.
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